Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evaxion Biotech ( (EVAX) ) has shared an update.
On May 12, 2026, Evaxion A/S reported that it will present new preclinical data on EVX-04, its AI-designed off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the European Hematology Association 2026 Congress in Stockholm. The poster, scheduled for June 13, 2026, will detail the functional characterization of EVX-04, which targets endogenous retroviral antigens and has shown tumor growth prevention and specific immune responses in preclinical models.
The company said the new findings mark another step towards clinical testing of EVX-04 and that it plans to move the program into the regulatory phase with a clinical trial application in the second half of 2026. By demonstrating broad tumor coverage and a ready-to-use vaccine format, the program underlines Evaxion’s ambition to position AI-designed off-the-shelf cancer vaccines as a potential new modality in AML, a field where current therapies yield limited long-term survival, especially in older and unfit patients.
The most recent analyst rating on (EVAX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Overall score reflects weak-to-mixed financial performance driven by continued losses and negative cash flow (despite a stronger balance sheet), partially offset by a positive earnings call emphasizing strong clinical/platform progress and a defined cash runway. Technicals are mildly supportive, while valuation is difficult to assess meaningfully due to negative earnings and no dividend.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a Denmark-based clinical-stage TechBio company that develops novel cancer and infectious disease vaccines using its proprietary AI-Immunology platform. The firm’s pipeline includes both personalized and off-the-shelf vaccine candidates, targeting high unmet medical needs by leveraging artificial intelligence for rapid target discovery and drug development.
Average Trading Volume: 30,339
Technical Sentiment Signal: Sell
Current Market Cap: $36.2M
See more data about EVAX stock on TipRanks’ Stock Analysis page.